Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind placebo-controlled study of subcutaneous B007 in generalized myasthenia gravis
CTR20240865Phase 3Completed
- Sponsor
- SPH Cross-linked
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of B007 in myasthenia gravis (MG), sponsored by SPH Cross-linked. Started Jul 2024; status: completed.
02
Drugs
B007
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20240865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240865.